decoration green curve

Company Introduction

About Us

G-NiiB GenieBiome, a biotechnology spinout from The Chinese University of Hong Kong was founded by world-renowned clinician-scientists and supported by a multidisciplinary team of experts in microbiology, metagenomics, bioinformatics, disease biomarkers, food technology, clinical trials, IP development and commercialization. For over a decade, our team has pioneered the use of microbiome with evidence-based science to tackle a myriad of diseases, including novel virus, gut serious illness, overweight and metabolic syndrome, skin irritation and mental health.

Our precision portfolio of G-NiiB GenieBiome includes diagnostic and risk prediction tests, next-generation microbiome precision formula, and precision medicine tailored for the Asian population.

Purpose

Microbiome offers infinite possibilities to human health. We create a unique solution for early disease detection, prevention and personalized treatment to bring health to mankind.

Vision

To be a game changer in human health with microbiome solutions.

Mission

To transform novel microbiome discoveries into effective diagnostics and therapeutics.

Value

Our passion is to bring health to Generation-Next with Innovation and Integrity in microBiome development.

Our Milestones

Come with us on a journey of our Company’s history of development! We are proud of the following milestones and achievements which have shaped us to who we are today.

JUN 2019
G-NiiB GenieBiome is established in Hong Kong
AUG 2020
G-Niib GenieBiome secures its Series A Funding
SEP 2020
A shared desk office is opened in Hong Kong
SEP 2020
G-Niib Immunity® SIM01, a microbiome precision formulation, is launched. 
APR 2021
G-Niib GenieBiome introduces M3CRC®, the world’s first non-invasive colorectal cancer risk prediction test that can detect non-advanced adenoma and adenoma recurrence
JUL 2021
The growing Hong Kong team relocates to a new office in 208 Johnston Road, Wan Chai, occupying half a floor
JUL 2021
G-Niib GenieBiome opens offices in Singapore and Malaysia
NOV 2021
The Company secures its Series B Funding 
JAN 2022
G-Niib GenieBiome expands its Hong Kong office to occupy the full floor in 208 Johnston Road, Wanchai
FEB 2022
G-NiiB M3XTRA® SMT04 is launched. This patented precision formula protects users against serious illness inducing bacteria. Clinical data show an average decrease of almost 40% of CRC/adenoma related bacteria after 4 weeks of continued use 
MAR 2022
G-Niib Immunity® SIM01 wins the Gold Medal at the 2022 Geneva International Exhibition of Inventions
MAR 2022
G-NiiB M3CRC® wins the Silver Medal at the 2022 Geneva International Exhibition of Inventions
APR 2022
The G-Niib Molecular and MicroBiome Laboratory is established
AUG 2022
Received Good MPF Employer Award 2021-22 by Mandatory Provident FundSchemes Authority
SEP 2022
G-NiiB Immunity SIM01® wins the NutraIngredients-Asia Probiotics of the Year Award 2022
NOV 2022
G-Niib Immunity® SIM01 scoops the NielsenIQ BASES Top Breakthrough Innovation Awards 2022
DEC 2022
G-Niib GenieBiome achieves HK$180 in revenue 
JAN 2023
Hong Kong Retail Management Association certifies G-Niib GenieBiome as a Quality E-shop and Trust E-shop
FEB 2023
G-Niib GenieBiome is awarded the Caring Company logo by The Hong Kong Council of Social Service 
MAR 2023
G-Niib GenieBiome further expands its Hong Kong office to occupy the second full floor at 208 Johnston Road, Wanchai
MAY 2023
Won the Gold Medal at the 2022 Geneva International Exhibition of Inventions: G-NiiB M3XTRA® SMT04
MAY 2023
Won the Silver Medal at the 2023 Geneva International Exhibition of Inventions: G-NiiB IMMUNE KIDS®
MAY 2023
Crowned MicroBiome Industry PaceSetter Award – Enterprise of the Year by China Gut Conference 2023
MAY 2023
Received the MircoBiome Innovation Award – High Potential Brand by Tmall Global and China Gut Conference 2023